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studied, the mechanisms of its initiation and chronic extension still 
remain to be resolved. Yet, it is clear that development of fibrosis 
after radiation cannot simply be explained by the function of one 
molecule, but requires the interplay of several cytokines and growth 
factors and multiple cell types.  
Our studies have identified the TGF-β co-receptor endoglin as new 
player in radiation-induced fibrosis development in the kidney. Mice 
expressing halved levels of endoglin (Eng+/-mice) displayed reduced 
fibrosis, but also less vascular damage after a single dose of kidney 
irradiation compared to irradiated Eng+/+ mice. This was accompanied 
by decreased mRNA expression of Tgfb1 and pro-fibrotic downstream 
targets such as Pai-1, Ctgf or Col3A1. We also noticed that 
development of fibrosis in the kidney was accompanied by infiltration 
of inflammatory cells, mainly macrophages. Macrophages are crucial 
for tissue repair, but may also promote kidney fibrosis by secreting 
pro-fibrotic growth factors and cytokines as shown in several models 
of kidney disease. Macrophage numbers were significantly upregulated 
in both irradiated Eng+/+ and Eng+/- kidneys; however, the upregulation 
was less pronounced in Eng+/- mice. In addition, expression of 
macrophage-expressed pro-inflammatory, pro-fibrotic and anti-
angiogenic cytokines interleukin 1-beta (Il1b) and interleukin 6 (Il6) 
was strongly reduced in the irradiated kidneys of Eng+/- compared to 
Eng+/+ mice.  
As endoglin is not only expressed on endothelial cells, but also on 
monocytes/macrophages, we are currently investigating whether 
changed endothelial cell function or an altered macrophage 
phenotype contributes to differential fibrosis formation in Eng+/+ and 
Eng+/-mice. We are also analysing whether macrophage depletion 
prevents fibrosis formation after kidney irradiation. Furthermore, we 
are testing whether the anti-inflammatory, immunomodulatory and 
anti-fibrotic drug Thalidomide impedes the development of radiation-
induced kidney fibrosis. 
In summary, we suggest that endoglin mediates the inflammatory 
response in irradiated tissues by regulating macrophage infiltration 
and cytokine production thereby contributing to the development of 
irradiation-induced kidney fibrosis.  
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Brachytherapy has benefited considerably from advances in imaging 
techniques in recent times. Tumour volumetric-based radiation 
planning based on excellent delineation of tumour anatomy has much 
improved our ability to target malignant tissue whilst sparing non-
malignant tissues. The highly conformal nature of Brachytherapy has 
further benefited from newer functional imaging techniques based on 
recognition of the altered biological and molecular processes 
occurring within tumour tissue. New paradigms for treatment planning 
and radiation delivery are now becoming possible based on the 
potential to define areas of varying functional activity within the 
anatomical tumour mass. Established 3D tumour volumes generated by 
morphological imaging techniques can now be modified by new 
information provided by functional imaging such as PET and MRI. 
Brachytherapy for prostate and Head & Neck cancers can benefit from 
data that quantifies areas of cellular and molecular disruptions within 
the tumour mass and thus offers the potential to individualise the 
Brachytherapy radiotherapy plan for each patient. 
Prostate Brachytherapy includes both High Dose Rate and Low Dose 
Rate techniques and has become widely adopted as a valid treatment 
for prostate tumours. Historically, imaging has played a relatively 
small role in the management of clinically localized prostate cancer 
but in more recent years, medical imaging techniques, such as TRUS, 
CT and MRI have improved the clinical management of patients with 
prostate cancer. Brachytherapy offers the possibility of better local 
treatment with less morbidity and improved outcomes; more accurate 
imaging has contributed to better staging and patient selection as well 
as more accurately image-guided treatment delivery.  
In the non-surgical treatment of head and neck tumours, 
Brachytherapy offers an excellent treatment for organ-preservation 
with local tumour control. Image guidance is central to the 
optimization of this treatment with careful dose escalation facilitated 
by accurate delineation of tumour and structures at risk. Adaptive 
image-guided Head & Neck Brachytherapy can complement newer 
surgical techniques and better understanding of tumour biology in this 
area will incorporate newer boost techniques also. 
The inherent goal of Brachytherapy is to safely deliver adequate 
radiation to those  areas of tumour tissue that are considered 
necessary based on our current understanding of tumour biology and 
radiation response. Imaging is central to the success of this 
treatment. 
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Before the era of breast conservation therapy using external beam 
radiotherapy (EBRT) and before the invention of linear accelerators 
and its widespread use in breast cancer treatment, brachytherapy 
using radium needles was the first method of breast irradiation. 
Interstitial breast implants started at the beginning of the XXth 
century either as mono-therapy or associated to surgery.  
Over the years, breast brachytherapy was less and less used but  it 
remained an option as a boost toEBRT. Nowadays with the increase 
use of partial breast irradiation, breast brachytherapy is gaining more 
importance.  Unlike prostate, breast brachytherapy is not widely 
practiced because it was always considered by many to be too 
operator and skill- dependent, partly because of the lack of easy and 
precise imaging.  It is evident that for more accuracy, imaging is 
necessary in breast brachytherapy as it is in EBRT, to plan and 
optimize the treatment. The need of accuracy is even more important 
in brachytherapy because it provides the most conformal coverage of 
tumor and normal tissue sparing radiotherapy technique.  
So in this era of highly targeted radiotherapy, breast brachytherapy 
faces the same challenges of volume delineation at each step of the 
process: in pre-planning, during implant and at dosimetry. The first 
step is the identification of the surgical bed to be implanted. This is 
not an easy task as reflected by the numerous papers in the 
literature. At the time of brachytherapy the cavity is often collapsed 
and difficult to find. We conducted a phase II study Using MRI imaging 
to help in the delineation of the surgical bed and therefore help to 
plan precisely where to place the implant. The second step is the 
precise placement of the interstitial needles into the breast around 
the target. This is of great importance since it will, in a way, 
determined the dosimetry. Ultrasound can be used as a step-by-step 
procedure. As in prostate brachytherapy a real-time imaging during 
the procedure would be ideal. The ultimate step, the dosimetry, is to 
maximize the dose to the target volumes and to minimize the dose to 
the adjacent organs at risk. At this step the quality of imaging is 
important for the delineation of the volumes and for reconstruction of 
the material implanted. CT scan allows implant reconstruction very 
easily but MRI allows accurate surgical bed delineation. Therefore a 
robust image fusion capacity has to be available.  Ultimately, the goal 
would be to find a 3D imaging modality that could serve both purposes 
and couldbe integrated in the treatment planning system. 
This presentation is aimed to determine the role of modern imaging 
modalities in all the steps of interstitial breast brachytherapy. It is our 
opinion that more accurate imaging will help the wide application of 
interstitial brachytherapy for breast cavity boost, partial breast 
irradiation and second conservative treatment for in-breast 
recurrences.  
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The ARTFORCE project (Adaptive and innovative Radiation Treatment 
FOR improving Cancer patients treatment outcomE) that now runs for 
more than a year, consists of two clinical trials, combined with 
fundamental research in molecular biology, i.e. predicting tumour 
response and physics: image guidance and dosimetry performed in a 
multi-institutional environment.   
The non-small cell lung cancer study aims to improve local control and 
test the hypothesis of iso-toxic dose redistribution. Patients are 
